Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - dulaglutide 3 mg/ml - solution for injection - 1.5 mg/0.5ml - active: dulaglutide 3 mg/ml excipient: citric acid mannitol polysorbate 80 sodium citrate dihydrate water for injection - type 2 diabetes mellitus: glycaemic control: trulicity is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: o as monotherapy. o in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 for data with respect to different combinations). type 2 diabetes mellitus: reduction in risk of major adverse cardiovascular events: trulicity is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have: o established cardiovascular disease or o multiple cardiovascular risk factors

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - galcanezumab 120 mg/ml - solution for injection - 120 mg/ml - active: galcanezumab 120 mg/ml excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sodium chloride water for injection - emgality is indicated for the prophylaxis of migraine in adults

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - galcanezumab 120 mg/ml - solution for injection - 120 mg/ml - active: galcanezumab 120 mg/ml excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sodium chloride water for injection - emgality is indicated for the prophylaxis of migraine in adults

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - pemetrexed disodium 151.7mg (as the heptahydrate, equivalent to pemetrexed free acid 100mg) - powder for infusion - 100 mg - active: pemetrexed disodium 151.7mg (as the heptahydrate, equivalent to pemetrexed free acid 100mg) excipient: hydrochloric acid mannitol sodium hydroxide water for injection - · alimta in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. · alimta as monotherapy is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - pemetrexed disodium 713mg (as the heptahydrate, equivalent to pemetrexed free acid 500mg) - powder for infusion - 500 mg - active: pemetrexed disodium 713mg (as the heptahydrate, equivalent to pemetrexed free acid 500mg) excipient: mannitol - alimta is indicated for the treatment of patients with malignant pleural mesothelioma in combination with cisplatin.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base - capsule - 100 mg - active: atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base excipient: dimeticone gelatin   iron oxide red   iron oxide yellow   pregelatinised maize starch sodium laurilsulfate   tekprint black sw-9008   tekprint black sw-9010   titanium dioxide   - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base - capsule - 10 mg - active: atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base excipient: dimeticone gelatin pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base - capsule - 18 mg - active: atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base excipient: dimeticone gelatin iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base - capsule - 25 mg - active: atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 45.71mg equivalent to 40 mg atomoxetine free base - capsule - 40 mg - active: atomoxetine hydrochloride 45.71mg equivalent to 40 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.